Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
October 25, 2004
- Hypertension GLs Revised
October 25, 2004
- PRESS SEMINAR
October 25, 2004
- Tanabe to Begin Research Using Human ES Cells Obtained in Japan
October 25, 2004
- BULLETIN
October 18, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 18, 2004
- EPMA Member Companies Report 9.8% Sales Growth in FY2003
October 18, 2004
- PRESS SEMINAR
October 18, 2004
- Survey Highlights Growing Awareness of GE Drugs: Sawai
October 18, 2004
- MONITOR
October 18, 2004
- Mr Morioka Calls For Mega-mergers of Domestic Firms
October 18, 2004
- MEDICAL DEVICE NEWS IN BRIEF
October 18, 2004
- Domestic SMO Market Showing Strong Growth: Survey
October 18, 2004
- Application of Nasal Endoscopy Increasing: Fujinon Toshiba
October 18, 2004
- Alfresa HD to Focus on Market Share in Tokai, Kansai Regions
October 18, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 18, 2004
- BUSINESS NEWS IN BRIEF
October 18, 2004
- PRESS SEMINAR
October 18, 2004
- 11 Drugs Including Trisrenox Inj. Approved
October 18, 2004
- Pemetrexed Approved in EU for Two Cancer Indications: Eli Lilly
October 18, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…